Report ID :10233568 |
Published Date : 21 Oct 2022 |
Report Format : |
Delivery Timeline :48-72 Business Hours
A biomarker is biological feature that can be used to measure the presence or progress of disease or the effects of treatment. For example, prostate specific antigen (PSA) is a biomarker for cancer of prostate. Biomarkers enable the researchers to quickly see large number of biological analytics. The global market value of the Global CNS Biomarker market is expected to be a billion dollar opportunity by 2018.and the size of the global CNS Biomarker market is expected to increase immensely by 2028, at a solid compound annual growth rate in 2018 – 2028.
In the present scenario, the research and development in CNS market has paced up due to support from government and private players. Additionally, FDA approvals are giving rise to significant scope in biomarker market. Moreover, Technological advancement in the CNS biomarker diagnostics enables to expand CNS biomarker market and innovations are giving rise to growth of CNS biomarker market. Presently, the global CNS biomarker market is undergoing rapid expansion with the discovery of new applications and the development of existing technologies. The key driving forces for the global CNS biomarker market are: Development in proteomics, genomics and imaging system in CNS biomarker. Funding from government and private players has also strengthened the CNS market. Increase in government spending/ private investment in healthcare budgets and R&D respectively, rising case of lifestyle related diseases and so on. Various factors such as High cost of CNS biomarker test and diagnostics are hindrances for the growth of CNS biomarker market. Reimbursement issues have left CNS biomarker market in doldrums.
The key players in global CNS biomarker market are Abastar MDX Inc, Thermo fisher scientific, Abiant Inc, EKFdiagnostics holdings Inc, Enzo biochem Inc, Acumen pharmaceuticals Inc, Adlyfe Inc, Alseres pharmaceuticals Inc, Apitope international, Aposense, Applied neurosolutions Inc, Avacta group plc, Merc & co. Inc, Avid radiopharmaceuticals Inc, Banyan biomarkers, Diagenic ASA, Exonhit therapeutics, Genenews ltd, Glycominds ltd, Great lakes neurotechnologies, Innogenetics biological, innovative neurotechnologies Inc, Metabolon Inc, Myriad RBM Inc, Oligomerix Inc, Opko health inc, Proteome sciences products, Ridge diagnostics and so on.
Companies Profiled
1. Abastar MDX Inc
2. Thermo fisher scientific
3. Abiant Inc
4. EKFdiagnostics holdings inc
5. Enzo biochem inc
6. Acumen pharmaceuticals Inc
7. Adlyfe Inc
8. Alseres pharmaceuticals Inc
9. Apitope international
10. Aposense
11. Applied neurosolutions Inc
12. Avacta group plc
13. Merck & co inc
14. Avid radiopharmaceuticals Inc
15. Banyan biomarkers
16. Diagenic ASA
17. Exonhit therapeutics
18. Genenews ltd
19. Glycominds ltd
20. Great lakes neurotechnologies
21. Innogenetics biologicals
22. Innovative neurotechnologies inc
23. Metabolon inc
24. Myriad RBM inc
25. Oligomerix inc
26. Opko health inc
27. Osta biotechnologies inc
28. Proteome sciences products
29. Psynova neurotech ltd
30. Ridge diagnostics
31. Satori pharmaceutical inc
32. Sabiosciences
This Occams Research Report covers
1. Historical data
2. Revenue forecasts, growth rates and CAGR upto 2028
3. Industry Analysis
4. Competitive Analysis
5. Key geographic growth data
6. In-depth profiling of companies
<
Why Choose Kenneth Research ?
-
Insight with Impact : We don’t just gather data — we uncover stories, trends, and opportunities that fuel business growth.
-
Experts Who Get It : Our team speaks your industry’s language and knows what really matters to your customers and market.
-
Custom-Built for You : Forget one-size-fits-all. We craft research and consulting solutions as unique as your business vision.
-
Partners, Not Just Providers : We work with you, not for you — collaborating closely to turn insights into smart, strategic moves.
-
Results That Speak : Our work powers brands, startups, and industry leaders alike — with a track record of ideas that work in the real world.
